Şunu aradınız:: farmokokinetika (Maltaca - İngilizce)

relazzjoni(jiet) farmokokinetika/farmakodinamika
pharmacokinetic/pharmacodynamic relationship(s)

il-farmokokinetika ta’ naloxegol fil-popolazzjoni pedjatrika ma ġietx studjata.
the pharmacokinetics of naloxegol in the paediatric population has not been studied.

inkisbet dejta dwar il-farmokokinetika għal dolutegravir, lamivudine u abacavir b’mod separat.
pharmacokinetic data have been obtained for dolutegravir, lamivudine and abacavir separately.

il-farmokokinetika ta’ pregabalin hija lineari fil-firxa tad-doża rrakkomandata kuljum.
pregabalin pharmacokinetics are linear over the recommended daily dose range.

il-farmokokinetika ta’ dutrebis fil-popolazzjoni tal-pazjenti pedjatriċi ma ġietx studjata fi studji kliniċi.
the pharmacokinetics of dutrebis in the paediatric patient population has not been studied in clinical studies.

id-dejta dwar il-farmokokinetika għal dolutegravir, abacavir u lamivudine f’individwi >65 sena ta’ età hija limitata.
pharmacokinetic data for dolutegravir, abacavir and lamivudine in subjects >65 years of age are limited.

użu flimkien ieħor studji speċifiċi li saru fuq jekk medicinali oħra ma jaqblux ma ’ dan il- prodott urew li m’ hemm l- ebda effett klinikament sinifikanti tal- prodotti mediċinali msemmija hawn taħt fuq il- farmokokinetika u l - farmakodinamika ta ’ ivabradine: impedituri proton pump (omeprazole, lansoprazole), sildenafil, impedituri hmg coa reductase (simvastatin), dihydropyridine calcium channel blockers (amlodipine, lacidipine), digoxin u warfarin.
15 other concomitant use specific drug-drug interaction studies have shown no clinically significant effect of the following medicinal products on pharmacokinetics and pharmacodynamics of ivabradine: proton pump inhibitors (omeprazole, lansoprazole), sildenafil, hmg coa reductase inhibitors (simvastatin), dihydropyridine calcium channel blockers (amlodipine, lacidipine), digoxin and warfarin.